Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma

NCT03200847 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03200847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03200847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma
Lead sponsor
University of Colorado, Denver
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2017
Completion date
October 19, 2022
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, stage iii melanoma, stage iv melanoma